News & Updates

Show Multimedia Only

Aspirin may protect against pancreatic cancer

16 Sep 2024

Use of aspirin appears to be beneficial in the prevention of pancreatic cancer, according to a study.

Aspirin may protect against pancreatic cancer

16 Sep 2024

Lower serum carotenoids a red flag for mortality in MAFLD

05 Sep 2024

Among patients with metabolic dysfunction-associated fatty liver disease (MAFLD), those with lower serum concentrations of α-carotene, β-carotene, β-cryptoxanthin, lycopene, and lutein/zeaxanthin are at heightened risk of all-cause and cardiovascular mortality, according to a study.

Lower serum carotenoids a red flag for mortality in MAFLD

05 Sep 2024

Genetic risk bolsters diet effects on hepatic steatosis, fibrosis

03 Sep 2024 by

The effect of certain dietary patterns on liver fat content (LFC) and iron-controlled T1 time (cT1, a measure of liver inflammation and fibrosis) may be elevated among patients who are at greater genetic risk for steatotic liver disease (SLD), suggests a study. This indicates that dietary interventions can be of benefit in this population.

Genetic risk bolsters diet effects on hepatic steatosis, fibrosis

03 Sep 2024

High-risk factors tied to new thrombotic events in NCPVT patients

02 Sep 2024

Interactions exist between high-risk factors for thrombosis and new thrombotic events in patients with noncirrhotic portal vein thrombosis (NCPVT) with local factors, reports a study.

High-risk factors tied to new thrombotic events in NCPVT patients

02 Sep 2024

Empagliflozin reduces hepatic fat content in nondiabetic MASLD patients

02 Sep 2024 by

Empagliflozin significantly reduces hepatic fat content vs placebo in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) without diabetes, researchers from the University of Hong Kong have reported.

Empagliflozin reduces hepatic fat content in nondiabetic MASLD patients

02 Sep 2024

Original New Drug Application Approvals by US FDA (1-15 August 2024)

30 Aug 2024

New drug applications approved by US FDA as of 1-15 August 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 August 2024)

30 Aug 2024

Novel GLP-1/GCG receptor agonist shows promise against noncirrhotic MASH with fibrosis

29 Aug 2024

Dual glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptor agonism with cotadutide has shown a signal of benefit in the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis, according to the phase II PROXYMO trial.